Genomic testing in voluntary workplace wellness programs in the US: Evidence and challenges.

Autor: Cohn B; Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, USA., Ryan KA; Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan, USA., Hendy K; Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA., Callahan K; Colby College, Waterville, Maine, USA., Roberts JS; Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan, USA.; Department of Health Behavior and Health Education, School of Public Health, University of Michigan, Ann Arbor, Michigan, USA., Spector-Bagdady K; Department of Obstetrics & Gynecology, Center for Bioethics and Social Sciences in Medicine, University of Michigan, Ann Arbor, Michigan, USA., Mathews DJH; Department of Genetic Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Jazyk: angličtina
Zdroj: Molecular genetics & genomic medicine [Mol Genet Genomic Med] 2023 Nov; Vol. 11 (11), pp. e2245. Date of Electronic Publication: 2023 Aug 17.
DOI: 10.1002/mgg3.2245
Abstrakt: Background: Workplace genetic and/or genomic testing (wGT) is one of many options that employers can offer within the scope of voluntary workplace wellness programs, though we know little about how many employers are offering this benefit, or what kinds of testing are included.
Methods: Our landscaping review sought to discover the prevalence and distribution of wGT within voluntary wellness programs among U.S. companies using three approaches: (1) analysis of publicly available information; (2) national surveys; and (3) interviews with company representatives.
Results: In total, 50/420 (11.9%) companies we investigated had publicly available data suggesting that they offer wGT to their employees. Survey data weighted to be representative of the type and distribution of U.S. companies suggest that ~1% of U.S. companies offer wGT to their employees.
Conclusion: Our research found little evidence of broad uptake of wGT among U.S. companies, though information gathering was challenging.
(© 2023 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje